Navigation Links
A Drug That Receives Regulatory Approval for Cognitive Impairment Associated With Schizophrenia Would Earn a Higher Patient Share in the United States Than in Europe

A Therapy's Effect on Executive Function and Functional Capacity are the Attributes that Most Influence Psychiatrists' Prescribing Habits, According to a New Report from Decision Resources

WALTHAM, Mass., Feb. 17 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that if a drug were to receive formal regulatory approval for the treatment of cognitive impairment associated with schizophrenia (CIAS), such an agent could earn up to 50 percent patient share in the United States and up to 33 percent patient share in Europe, according to surveyed U.S. and European psychiatrists.

The new report entitled Cognitive Impairment Associated with Schizophrenia: Emerging Consensus Expected to Define a New Indication as Physicians Await the Launch of the First Approved Drug finds that a therapy's effect on executive function (reasoning and problem solving) and functional capacity (ability to manage daily tasks) are the attributes that most influences psychiatrists' prescribing decisions in CIAS. To date, no drugs are formally approved for CIAS and off-label treatment is sporadic. However, clinical data and the opinions of interviewed thought leaders indicate that the currently-available therapy, modafinil (Cephalon's Provigil), as well as emerging agents from Roche/Memory Pharmaceuticals, Allon Therapeutics, Cephalon and Merck could demonstrate advantages in treating CIAS when compared with donepezil (Eisai/Pfizer's Aricept, Bracco's Memac), the sales-leading agent in this virtually untapped market.

"In rare cases when psychiatrists elect to prescribe off-label therapy for CIAS, such as donepezil, their choice of treatment is based in large part on a drug's proven benefits in other indications in the hopes that CIAS patients will experience similar benefits," said Decision Resources Analyst Jonathan Searles. "However, thanks to evolving consensus about clinical trial design and the most promising drug targets in CIAS, a growing number of developers are investigating novel compounds for the treatment of this new indication."

About the Report

Cognitive Impairment Associated with Schizophrenia: Emerging Consensus Expected to Define a New Indication as Physicians Await the Launch of the First Approved Drug is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    Decision Resources                   Decision Resources, Inc.
    Christopher Comfort                  Elizabeth Marshall
    781-296-2597                         781-296-2563    

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. i.HUG Foundation Receives International Grant: Hires a School Nurse to Improve Student Health and Learning
2. Emageon Receives Escrowed Funds and Terminates Merger Agreement
3. Children's National Medical Center Trauma Center Receives Highest Verification from American College of Surgeons
4. Abbott Receives FDA Clearance for New CELL-DYN(R) Emerald(TM) Hematology Instrument
5. Rising Medical Solutions Receives URAC Workers Compensation Utilization Management Accreditation
6. Executive Board Member of National Patient Advocate Foundation, Patient Advocate Foundation Receives National Institutes of Health 2008 Health Disparities Excellence Award
7. Nationwide Receives IBI/NBCH Healthy Workforce Productivity Award
8. Boston Medical Center cardiologist receives Drake Award
9. Priligy(TM) (Dapoxetine) Receives First Regulatory Approvals for the Treatment of Premature Ejaculation (PE) in Finland and Sweden
10. Blue Cross Receives Disease Management Awards
11. ARKRAY USA Receives FDA Clearance on GLUCOCARD(R) 01-mini Blood Glucose Monitoring System
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... ... strategic partnership with Connance, a healthcare industry leader providing predictive analytics to ... technology combine to provide health systems, hospitals and ambulatory surgical centers with ...
(Date:6/26/2016)... , ... June 26, 2016 , ... Pixel Film Studios ... X. , "Film editors can give their videos a whole new perspective by using ... - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can ... Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey ... cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell ... pain and the benefits of holistic treatments, Serenity Recovery Center of Marne, ... Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 /PRNewswire/ ... Diabetes Tomorrow,s Leaders Scholarship is any indication, the future ... today online at by the Diabetes ... stand in the way of academic and community service ... scholarship program since 2012, and continues to advocate for ...
(Date:6/23/2016)... 23, 2016 The vast majority of dialysis ... facility.  Treatments are usually 3 times a week, with ... including travel time, equipment preparation and wait time.  This ... grueling for patients who are elderly and frail.  Many ... and rehabilitation centers for some duration of time. ...
Breaking Medicine Technology: